Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Palbociclib in Solid Tumors
NCT02065063Phase 1Completed
- Sponsor
- GSK
- Start
- Apr 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trametinib and palbociclib in solid tumor and cutaneous melanoma (CM) (3 arms), sponsored by GSK. Primary endpoints: Change from baseline in vital signs up to 36 months, Change from baseline in physical examination findings up to 36 months and 7 more. Started Apr 2014; status: completed.
02
Drugs
trametinibpalbociclib
03
Conditions
solid tumorcutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT02065063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065063.